HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AES-135

a hydroxamic acid-based HDAC inhibitor

Also Known As:

4-((4-tert-butylphenyl)methyl-(2-((4-fluorophenyl)sulfonyl-((2,3,4,5,6-pentafluorophenyl)methyl)amino)acetyl)amino)-N-hydroxybenzamide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Adile, Ashley A: 1 article (01/2019)
2.	Bakhshinyan, David: 1 article (01/2019)
3.	Berger-Becvar, Angelika: 1 article (01/2019)
4.	Deininger, Michael W: 1 article (01/2019)
5.	Fishel, Melissa L: 1 article (01/2019)
6.	Gawel, Justyna M: 1 article (01/2019)
7.	Geletu, Mulu: 1 article (01/2019)
8.	Grimard, Michelle L: 1 article (01/2019)
9.	Gunning, Patrick T: 1 article (01/2019)
10.	Heaton, William L: 1 article (01/2019)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2019 - "In an orthotopic murine model of pancreatic cancer, AES-135 prolongs survival significantly, therefore representing a candidate for further preclinical testing." 01/01/2019 - "Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer."
2.	Neoplasms (Cancer) 01/01/2019 - "In a three-dimensional coculture model, AES-135 kills low-passage patient-derived tumor spheroids selectively over surrounding cancer-associated fibroblasts and has excellent pharmacokinetic properties in vivo. "

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Hydroxamic Acids (Hydroxamic Acid)